3
Announcements
Trials
Browse
Landscape
Phase
Phase 4
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Dermatologic
1
Conditions
Melanoma
3
Neoplasm Metastasis
2
Skin Neoplasms
1
Recurrence
1
Prostatic Neoplasms
1
Oligodendroglioma
1
Neuroectodermal Tumors, Primitive
1
Neoplasms, Plasma Cell
1
Multiple Myeloma
1
Meningioma
1
Lymphoma, Non-Hodgkin
1
Lymphoma
1
Leukemia, Myeloid, Acute
1
Gliosarcoma
1
Glioma
1
Glioblastoma
1
Ependymoma
1
Carcinoma, Renal Cell
1
Brain Neoplasms
1
Astrocytoma
1
Interventions
pembrolizumab
23
Nivolumab
22
aldesleukin
21
Cyclophosphamide
20
Ipilimumab
17
Interleukin-2
17
fludarabine
15
fludarabine phosphate
14
cemiplimab
12
Radiotherapy
7
Fluorouracil
7
Dacarbazine
6
binimetinib
5
Vemurafenib
5
Temozolomide
5
Surgical Procedures, Operative
5
Sirolimus
5
Radiation
5
Biopsy
5
Aminolevulinic Acid
5
encorafenib
4
dabrafenib
4
Photochemotherapy
4
Educational Status
4
trametinib
3
sonidegib
3
montanide ISA 51
3
avelumab
3
Tacrolimus
3
Sodium Chloride
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Skin Neoplasms
×
Interleukins
×
Clear all
NCT01856023
2023-12-05
PROCLIVITY02
Clinigen, Inc.
Phase 4
Terminated
29 enrolled
9 charts